Hepatitis B virus control: Identifying proteins in mutation management

(Medical Xpress)—Researchers at Kanazawa University Graduate School of Medical Science in Japan have determined how APOBEC proteins mediate hypermutations that inhibit viral replication. They also identify the host factor protein UNG that can repair these mutations. This research is also described in the inaugural June 2013 issue of the Kanazawa University Research Bulletin.

The (HBV) is a primary cause of . So far the persistence of the virus has not been fully explained. Recently researchers showed that a group of proteins – apolipoprotein B mRNA editing catalytic polypeptide (APOBEC) proteins – were found to inhibit replication of the virus but the exact mechanism remained a mystery. Now researchers at Kanazawa University Graduate School of Medical Science in Japan have determined how APOBEC proteins mediate hypermutations that inhibit . They also identify the host factor protein UNG that can repair these mutations.

The HBV genome form is converted into stable covalently closed circular DNA (cccDNA) in the nuclei of cells when they are infected. As the authors point out, "cccDNA is not targeted by anti-HBV drugs and thus enables the re-establishment of viral replication after cessation of antiviral therapy." However the lack of an experimental system that can produce cccDNA in sufficient quantities for investigation has limited what is known about the host factors that control cccDNA.

Masamichi Muramatsu and colleagues at Kanazawa University Graduate School of Medical Science used an avian counterpart for HBV – duck HBV (DHBV) – to investigate the role of the host factor UNG in viral hypermutation in cccDNA. DHBV shares many similarities with HBV with an important advantage for experimental investigation; it reproduces cccDNA more efficiently.

Transfection experiments showed that cccDNA hypermutation was enhanced on UNG inhibition in APOBEC3G expressing cells, resulting in a significant decrease in viral production. "We speculate that the balance between AID/APOBECs and UNG activities on mutation frequency decides the consequence to hepadnaviruses: deleterious mutations vs. diversification," suggest the researchers. Their future research will look into the possible role of APOBECs and factors like UNG in the emergence of drug-resistant mutants of HBV and DHBV.

More information: Kitamura, K. et al. Uracil DNA Glycosylase Counteracts APOBEC3G-Induced Hypermutation of Hepatitis B Viral Genomes: Excision Repair of Covalently Closed Circular DNA, PLoS Pathog 9(5): e1003361. doi:10.1371/journal.ppat.1003361.

Related Stories

Novel therapeutic approaches to cure chronic HBV infection

Apr 25, 2013

Exciting new data presented today at the International Liver Congress 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for ...

Androgen boosts hepatitis B virus replication

Feb 16, 2012

Androgen enhances replication of hepatitis B virus (HBV), rendering males more vulnerable than females to this virus, according to research published in the February Journal of Virology.

Recommended for you

US orders farms to report pig virus infections

18 hours ago

The U.S. government is starting a new program to help monitor and possibly control the spread of a virus that has killed millions of pigs since showing up in the country last year.

Foreigner dies of MERS in Saudi

19 hours ago

A foreigner has died after she contracted MERS in the Saudi capital, the health ministry said on announced Friday, bringing the nationwide death toll to 73.

Vietnam battles fatal measles outbreak

22 hours ago

Vietnam is scrambling to contain a deadly outbreak of measles that has killed more than 100 people, mostly young children, and infected thousands more this year, the government said Friday.

New clues on tissue scarring in scleroderma

23 hours ago

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

User comments